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Mitochondria are dynamic organelles that play a
central role in a diverse array ofmetabolic processes.
Elucidating mitochondrial adaptations to changing
metabolic demands and the pathogenic alterations
that underlie metabolic disorders represent principal
challenges in cell biology. Here, we performed multi-
plexed quantitative mass spectrometry-based pro-
teomics to chart the remodeling of the mouse liver
mitochondrial proteome and phosphoproteome
during both acute and chronic physiological transfor-
mations in more than 50 mice. Our analyses reveal
that reversible phosphorylation is widespread in
mitochondria, and is a key mechanism for regulating
ketogenesis during the onset of obesity and type 2
diabetes. Specifically, we have demonstrated that
phosphorylation of a conserved serine on Hmgcs2
(S456) significantly enhances its catalytic activity in
response to increased ketogenic demand. Collec-
tively, our work describes the plasticity of this organ-
elle at high resolution and provides a framework
for investigating the roles of proteome restructur-
ing and reversible phosphorylation in mitochondrial
adaptation.
INTRODUCTION
Mitochondria are key centers of metabolism and signaling for
nearly all eukaryotic cells (Nunnari and Suomalainen, 2012).
Mitochondrial dysfunction is associated with a spectrum of
rare inborn errors of metabolism and an increasing number of
common diseases including Parkinson’s, Alzheimer’s, various
cancers, and type 2 diabetes (T2D) (Nunnari and Suomalainen,
2012; Szendroedi et al., 2012). Recent large-scale efforts have
helped to define the mammalian mitochondrial proteome and672 Cell Metabolism 16, 672–683, November 7, 2012 ª2012 Elsevierto reveal its variability across tissues (Foster et al., 2006; John-
son et al., 2007; Pagliarini et al., 2008). Collectively, this work
has advanced our understanding of basic mitochondrial biology
and has catalyzed the discovery of gene mutations underlying
many mitochondrial diseases (Calvo and Mootha, 2010). None-
theless, important steps remain for achieving a systems-level
understanding of this organelle and its contribution to disease
pathophysiology. These include elucidating the proteome re-
modeling that accompanies conditions involving mitochondrial
dysfunction and, more comprehensively, defining the role of
posttranslational modifications (PTMs) in regulating mitochon-
drial protein activities.
Mounting evidence suggests that mitochondrial adaptation
relies on a range of reversible PTMs. Already, focused efforts
have linked the importance of these modifications to apoptosis,
oxidative phosphorylation, the hypoxia response, andmitochon-
drial biogenesis (O’Rourke et al., 2011; Pagliarini and Dixon,
2006), and large-scale studies have revealed that much of the
mitochondrial proteome is phosphorylated (Boja et al., 2009;
Deng et al., 2010; Zhao et al., 2011) or acetylated (Guan and
Xiong, 2011). Nevertheless, our understanding of specific protein
and PTM alterations that affect mitochondrial function remains in
its infancy. This is principally due to the fact that large-scale
investigations of PTMs often fail either to identify the specific
sites of modification or to quantify how these modifications
(and the abundances of the modified proteins) change in a
condition-specific manner.
Here, we performed multiplexed quantitative proteomics and
site-specific phosphoproteomics of mouse liver mitochondria
acrossa seriesof contrastingbiological states (Figure1AandFig-
ure 4A). We analyzed lean (wild-type) and obese (leptin-deficient)
mice at two ages (4 weeks or 10 weeks), each from two strains
(C57BL/6J [B6] and BTBR). These analyses were primarily moti-
vatedby the suspectedcontribution ofmitochondrial dysfunction
to the onset of obesity and insulin resistance (Szendroedi et al.,
2012), and by the sharp contrast in T2D susceptibility between
these two strains (Keller et al., 2008). To achieve extensive
coverage, and to quantify fold changes between conditions, we
conducted five independent eight-way comparisons (40 miceInc.
Figure 1. Large-Scale, Multiplexed Proteomic and Phosphoproteomic Analyses of Mouse Liver Mitochondria
(A) We performed our initial analyses in two phases (left): a univariate experiment (eight mice, two conditions), and a multivariable experiment (40 mice, all eight
conditions depicted). Our workflow (right) involved enriching mitochondria from liver and performing high-resolution quantitative proteomic/phosphoproteomics
with eight-plex iTRAQ.
(B) Unsupervised hierarchical clustering of four lean (L) and four obese (O) mice (univariate). Values aremean protein abundance, relative to the average of all eight
mice, on a log2 scale from <1 to >1.
(C) Abundance of fatty acid oxidation proteins in lean (light gray) and obese (dark gray) mice (univariate), using the same units as in (B). Error bars indicate SD, and
crosses (y) indicate significant differences between lean and obese mice (q < 0.1).
(D) Volcano plot of fold phosphorylation change (normalized to protein abundance) versus log (p value) for mitochondrial (red) and nonmitochondrial (gray)
phosphosites (univariate).
(E) Abundance fold change (obese/lean) for all proteins with significant obesity-dependent alterations (q < 0.1) in B6 mice at 10 weeks in both experiments
(multivariate on the x axis and univariate on the y axis). The percent of measurements in discordance between the two studies (light gray dots) is indicated.
(F) Unsupervised hierarchical clustering of each condition from themultivariate experiment based onmitochondrial proteins quantified in all five replicates. Values
are mean abundance for each condition, relative to all eight conditions, on a log2 scale from <1 to >1.
(G) Abundance fold changes for individual oxidative phosphorylation proteins (each represented by a circle, separated by OxPhos complexes) in the univariate
experiment (obese/lean in light gray) and the multivariate experiment (obese 10-week B6 relative to all other conditions in black, obese 10-week BTBR relative to
all other conditions in red). See also Table S6.
(H) Summary of protein and phosphorylation data. IDs, identifications at 1% FDR; Quant, measurements quantified with iTRAQ reporter ions in at least one
comparison; (D), measurements significantly changing between any condition that was measured (q < 0.1). Results are shown for both mitochondrial proteins
(MitoCarta) and all proteins identified (Total), in both the univariate and multivariate experiments. See also Figure S1, Table S1, Table S2, Table S3, Table S4, and
Table S5.
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mass spectrometry (MS) with isobaric tagging (Lee et al., 2011;
Phanstiel et al., 2011; Ross et al., 2004; Thompson et al., 2003).Cell MUsing this same approach, we also assessed the reversibility
of these modifications in wild-type B6 mice during acute fast-
ing and refeeding (Figure 4A). Collectively, we identified 811etabolism 16, 672–683, November 7, 2012 ª2012 Elsevier Inc. 673
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ported—on 295 mitochondrial proteins, and have revealed that
a largeproportion of thesemodifications are dynamic and revers-
ible during these acute and chronic transformations.
We leveraged this quantitative data set to reveal that phos-
phorylation is an important mechanism for regulating ketone
body production. We have demonstrated that Hmgcs2, which
catalyzes the first committed step of ketogenesis (Reed et al.,
1975), is phosphorylated on ten separate residues. Phosphoryla-
tion of five of these sites changes dynamically across our biolog-
ical conditions (q < 0.1), and at least one—phosphorylation of
serine 456—significantly enhances enzyme activity. We have
further shown that phosphorylation of this site occurs in
response to increased ketogenic demand both in cell culture
and in our mouse models, whose serum b-hydroxybutyrate
(b-HB) increases with obesity and the onset of T2D. Our protein
and phosphorylation compendium, termed MitoMod, is freely
available at http://mitomod.biochem.wisc.edu.
RESULTS AND DISCUSSION
Comparative Proteomic Analyses of Mouse Liver
Mitochondria
The goal of our initial proteomic analyses was to establish
a comprehensive and quantitative map of mitochondrial protein
abundance and site-specific protein phosphorylation levels
across the contrasting biological conditions of age, mouse
strain, and obesity status. To do so, we performed these anal-
yses in two phases. In the univariate phase, we analyzed liver
mitochondria from four lean (wild-type) and four obese (leptin/,
ob/ob) 10-week-old B6 mice (Figure 1A). This initial phase
enabled us to assess the breadth and depth at which our analysis
platform could detect changes to the mitochondrial proteome
and phosphoproteome. In the multivariate phase, we analyzed
40 mice differing by three variables: age, strain, and obesity
(Figure 1A). These animals included lean (wild-type) and obese
(ob/ob) mice from both diabetes-susceptible (BTBR) and dia-
betes-resistant (B6) strains, each as either adolescents (4 weeks
of age) or adults (10 weeks of age).
For each phase, we purified mitochondria only to the extent
required to achieve near-comprehensive coverage of the liver
MitoCarta protein list, allowing us to simultaneously profile cop-
urifying organelles (MitoCarta is a tissue-specific compendium
of mitochondrial proteins complied using MS-based proteomic
analyses of highly purified mitochondria, machine learning, and
GFP microscopy [Pagliarini et al., 2008]). Our univariate phase
identified 3,447 unique proteins and 3,895 unique phosphoiso-
forms (site-specific phosphorylation patterns) from just over 1
million MS/MS scans. These include 692 of the 700 liver
MitoCarta proteins, and 449 mitochondrial phosphoisoforms.
Notably, unsupervised hierarchical clustering of the protein
abundance measurements appropriately grouped the mice
by their obesity status (Figure 1B). After correcting for multiple
hypotheses, significant differences (q < 0.1) in abundance were
observed for 1,014 proteins (325 mitochondrial, Figures 1H
and see Figure S1B online) and 720 phosphoisoforms (102 mito-
chondrial, Figure 1H and Figure S1D).
Our univariate data revealed extensive and reproducible re-
modeling of the liver mitochondrial proteome and phosphopro-674 Cell Metabolism 16, 672–683, November 7, 2012 ª2012 Elsevierteome with obesity (Figures 1B–1D, Figures S1B–S1D). For
example, fatty acid oxidation and oxidative phosphorylation
(OxPhos) proteins were increased with obesity (Figures 1C and
1G), while reactive oxygen species (ROS) detoxification en-
zymes were decreased (Figure S1C), consistent with known liver
alterations (Buchner et al., 2011; Deng et al., 2010; Wang et al.,
2012a). Phosphorylation changes were also prominent in a
range of central mitochondrial (and nonmitochondrial) pathways
(see http://mitomod.biochem.wisc.edu and Table S1, Table S2,
Table S3, Table S4, and Table S5). For example, the three most
statistically significant changes (q < 0.002) in phosphorylation
of MitoCarta proteins in this phase were found on enzymes
involved in ketogenesis (Hmgcs2), lipogenesis (Gpam), and
retinol metabolism (Dhrs4)—pathways key for proper liver func-
tion and linked to changes caused by obesity (Bonet et al., 2012;
Szendroedi et al., 2012).
Given the efficacy of our univariate phase, we proceeded to
analyze 40 additional mice in our multivariate phase (Figure 1A).
This experiment enabled us to identify changes linked to specific
variables including age, obesity status, mouse strain, and com-
binations thereof (see Figure S1A for a description of all compar-
isons). Here, we identified 3,684 unique proteins, including 98%
of the liver mitochondrial proteins previously identified by MS in
the MitoCarta study (Pagliarini et al., 2008). Of the 5,948 unique
phosphoisoforms identified, 508 are on mitochondrial proteins.
Interestingly, hierarchical clustering of MitoCarta protein abun-
dances grouped these mice primarily by strain, with secondary
groupings of either obesity status (B6) or diabetic status
(BTBR) (Figure 1F). Our data also reveal that the diabetic 10-
week-old BTBR mice, opposite their B6 counterparts, have
repressed expression of glycolytic and TCA cycle enzymes (Fig-
ure S1G, Table S6), consistent with a ketogenic state (Berry
et al., 1983). Similarly, while OxPhos proteins are induced with
obesity in B6 mice, they are decreased in obese hyperglycemic
BTBR mice (Figure 1G, Table S6), perhaps partially explaining
discrepancies in the effects of obesity on liver mitochondrial
respiration in different mouse models (Buchner et al., 2011;
Holmstro¨m et al., 2012).
Across all conditions assessed in these two phases, we have
identified significant changes (q < 0.1) in 268 mitochondrial
phosphoisoforms on 136 proteins, and abundance alterations
for 534 mitochondrial proteins. Importantly, our separate anal-
yses also demonstrate that ourmeasurements are both accurate
and reproducible (Figures 1B–1E, Figures S1B–S1F). Together,
these analyses begin to capture the global plasticity of the
mitochondrial proteome, and highlight individual proteins and
pathways in this organelle that are key to cellular metabolic
adaptation during various physiological transformations (Fig-
ure 1H, Table S1, Table S2, Table S3, Table S4, and Table S5).
A Quantitative Map of Mitochondrial Phosphoproteome
Dynamics
The results of our univariate and multivariate experiments
expand the number of known mouse liver mitochondrial phos-
phosites by 123 (including many on proteins of low abundance,
Figure S2), while capturing 77% of those reported previously
(Huttlin et al., 2010; Lee et al., 2007; Monetti et al., 2011; Ville´n
et al., 2007). Our analyses also help to discern which proteins
might be particularly important targets of phosphorylation inInc.
Figure 2. Dynamic Phosphorylation of Key Mitochondrial Proteins
(A–D) Identification of phosphorylation sites within key mitochondrial path-
ways: (A) oxidative phosphorylation (OxPhos), (B) ketone body production, (C)
the TCA cycle (and related enzymes), (D) fatty acid oxidation. Phosphorylation
sites exhibiting significant changes (q < 0.1) are in red; sites that are not
changing significantly are in gray; and sites identified, but not quantified, are
represented as white circles. See also Figure S2.
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into pathways and complexes (Figure 2), it is clear that certain
proteins have a disproportionately high number of phosphoryla-
tion sites, even when the corresponding proteins are each de-
tected at comparable levels. Such proteins include Atp5a1 of
the OxPhos machinery (Figure 2A) and Hmgcs2 of the ketogen-
esis pathway (Figure 2B), which each have at least 3-fold more
phosphorylation sites than other members of their respective
pathways. Second, by comparing our data with a recent muscle
phosphoproteomic study (Zhao et al., 2011), we find a high
degree of overlap in phosphorylation targets for certain path-
ways (e.g., 15 of our 27 phosphorylated OxPhos subunits, Fig-
ure 2A), suggesting that a common set of proteins are subject
to phosphorylation in different tissues. Third, because our
approach quantifies phosphorylation levels across a range of
conditions, we can identify sites that are modified dynamically.
We find that a large proportion (41%) of mitochondrial phosphor-
ylation levels significantly and reproducibly change (q < 0.1)
between at least one of our comparison groups (Figure S1A).
As illustrated in Figure 2A, residues on 14 of the 27 phosphory-
lated OxPhos subunits noted above are subject to dynamic
phosphorylation (q < 0.1), and thus represent likely regulatory
sites (red dots in Figure 2A).
The design of our multivariate study enables us to associate
specific protein and phosphorylation changes with particularCell Mphysiological transitions. Of the 235 mitochondrial phosphoiso-
forms that significantly change in our multivariate data set (q <
0.1), 134 demonstrate associations with age, mouse strain, or
onset of obesity, independent of other factors (Figure 3A, Table
S3). For example, phosphorylation of serine 162 on Lactb in-
creases specifically in an age-dependent manner in both strains,
regardless of their obesity status (Figure 3B). The increased
phosphorylation of Lactb on S162 in 10-week-old mice could
potentially contribute to the development of obesity in adult
mice, as the Lactb gene has been causally linked with this condi-
tion (Chen et al., 2008). Likewise, the phosphorylation levels of
serine 55 on Acadl and threonine 46 on Slc25a5 were signifi-
cantly altered in strain- and obesity-centric manners, respec-
tively (Figure 3B). Acadl catalyzes the first step in mitochondrial
b-oxidation of long straight-chain fatty acids (Lea et al., 2000).
We hypothesize that the increase in phosphorylation of S55 on
Acadl in BTBR mice promotes enhanced lipid oxidation, consis-
tent with their resistance to the development of fatty liver (Wang
et al., 2012a). Collectively, these examples of condition-specific
changes in mitochondrial phosphorylation reveal how our data
can be leveraged to generate hypotheses about how a given
site affects protein function and to elucidate important mito-
chondrial processes that are altered in defined physiological
states.
Acute Mitochondrial Phosphorylation Changes during
Fasting/Refeeding
Our multivariate analyses described above provide a map of
the liver mitochondrial phosphoproteome, and describe how
individual phosphosites are altered during gradual, long-term
physiological changes. Next, to ensure that many of the phos-
phorylation events we detect represent reversible sites of modi-
fication, and to further refine our hypotheses about the function
of individual phosphosites, we measured changes in the mito-
chondrial phosphoproteome during an acute fasting/refeeding
experiment. Here, eight lean (wild-type) B6 mice were fasted
overnight (16 hr), after which half of the animals were allowed
to feed ad libitum for 2 hr (Figure 4A). Serummetabolite analyses
revealed the expected refeeding responses: insulin and glucose
levels were elevated, and b-HB and triglyceride levels were
diminished in refed versus fasted animals (Figure 4B).
Refeeding caused rapid changes to 88MitoCarta phosphoiso-
forms (58 decreasing and 30 increasing at q < 0.1), with generally
small or nonexistent underlying changes to protein levels (Fig-
ure 4D). Notably, these included expected decreases (Pagliarini
and Dixon, 2006) in the phosphorylation of pyruvate dehy-
drogenase E1a S232, S293, and S300 and branched-chain ke-
toacid dehydrogenase E1 S338 (Figure 4C). Likewise, expected
changes to nonmitochondrial proteins were observed, including
increased phosphorylation of glycogen synthase kinase 3 alpha
S21 (Fang et al., 2000) and decreased phosphorylation of inositol
1,4,5-triphosphate receptor 1 S1588 (Wang et al., 2012b) (Fig-
ure 4C). We again observe dynamic phosphorylation on mito-
chondrial proteins from a wide range of processes, including
oxidative phosphorylation (Atp5a1, Atp5j, Ndufv3, Cox4i1), the
TCA cycle (Idh3g), fatty acid oxidation (Acaa1b, Acadvl, Hadha,
Ehhadh), the urea cycle (Glud1, Slc25a13, Otc, Cps1), hormone
metabolism (Comt), and glycerolipid biosynthesis (Gpam). These
dynamic phosphorylation events could contribute to knownetabolism 16, 672–683, November 7, 2012 ª2012 Elsevier Inc. 675
Figure 3. State-Specific Mitochondrial Phosphorylation
(A) Heatmap showing unsupervised hierarchical clustering of all quantified mitochondrial phosphoisoforms across each single-variable comparison; strain (S),
age (A), and obesity (O). Values are fold changes between all mice differing by the indicated variable, on a log2 scale from <1 to >1.
(B) (Top) Eight-plex iTRAQ-based quantification of phosphorylation of Acadl serine 55, Lactb serine 162, and Slc25a5 threonine 46 is shown for each condition
(with error bars representing SD from all replicates quantified) relative to the average of all eight conditions. (Bottom) The same data analyzed with relative
abundance reflecting the fold change (log2 scale) between all 40 mice of the multivariate experiment separated by one variable at a time (e.g., strain analysis
represents all 20 B6 mice versus all 20 BTBR mice). The colored bars correspond to the comparisons, with the data points highlighted in black on the top panel
serving as the numerator and those in white as the denominator. Crosses (y) indicate significance at q < 0.1.
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obesity (Nunnari and Suomalainen, 2012; Szendroedi et al.,
2012). These data also suggest that proteins involved in heme
biosynthesis (Alas1), synthesis of mitochondrial-specific fatty
acids (Mcat), and protein translation (Rg9mtd1, Mrpl1, Mrpl45,
Mrps36), among others, are subject to rapid, posttranslational
regulation in response to refeeding (Figure 4D, Table S7). Collec-
tively, this analysis demonstrates that mitochondrial protein
phosphorylation is reversible and responsive to acute metabolic
perturbations.
Kinase Activities Predicted via Phosphopeptide Data
Our observation that dynamic phosphorylation is widespread
among mitochondrial proteins motivated us to investigate which
kinases might be performing these modifications. To do so, we
employed two phosphosite analyses. First, we directly searched
our data for phosphorylation within known kinase motifs, as
defined in the PHOSIDA database (Gnad et al., 2011). This anal-
ysis suggested that a wide variety of kinases might be active in
this organelle: 13 different kinases were each associated with
at least 20 MitoCarta phosphosites (Figure 5A). This analysis,
however, does not take into account the frequency at which
each sequence appears in the proteome and is biased toward
established kinase motifs. Given these shortcomings, we also676 Cell Metabolism 16, 672–683, November 7, 2012 ª2012 Elsevieranalyzed our data using the Motif-X algorithm (Schwartz and
Gygi, 2005), which identifies amino acid residues overrepre-
sented at specific positions around phosphorylation sites.
Motif-X analysis revealed four such amino acid sequences
around MitoCarta phosphosites, including those that loosely
match to the CK2 (sxxE) and PKA (Rxxs) consensus motifs (Fig-
ure 5B). Together, these analyses suggest that PKA and CK2 are
among the active kinases inmitochondria, consistent with recent
phosphomotif analysis of muscle mitochondrial proteins (Zhao
et al., 2011), and with reports of PKA phosphorylating complex
IV subunits (Acin-Perez et al., 2009). Furthermore, across our
entire multivariate data set (mitochondrial and nonmitochondrial
proteins), phosphorylation levels on proteins with putative PKA
and CK2 motifs increase in an age- and obesity-dependent
manner (p < 0.05), suggesting that these kinasesmay be respon-
sible for some of the increased mitochondrial phosphorylation
seen following these transitions (Figure 5C; see Figure S3 and
Table S1, Table S2, Table S3, Table S4, and Table S5 for all motif
and kinase activity predictions).
Phosphorylation of Serine 456 on Hmgcs2 Promotes
Ketogenesis
The combination of our quantitative phosphoproteomics data
and kinase activity predictions enabled us to predict whichInc.
Figure 4. Acute Phosphorylation Changes across the Mitochondrial
Proteome upon Fasting and Refeeding
(A) Eight lean B6 mice were fasted overnight (16 hr), after which half of the
animals were allowed to feed ad libitum for 2 hr. Liver mitochondria were
isolated and subjected to the same proteomic/phosphoproteomics workflow
as described in Figure 1.
(B) The indicated metabolites were measured from serum, with error bars
indicating SEM and asterisks (*) indicating significance at p < 0.05.
(C) Phosphorylation fold change (log2 scale) for selected regulatory sites, ex-
pressed as refed/fasted with crosses (y) indicating significance at q < 0.1.
(D) All mitochondrial proteins (MitoCarta) quantified are ranked on the x axis by
protein abundance fold change (black dots). Relative quantitation of mito-
chondrial phosphoisoforms (each represented by a single red dot) is plotted at
the same position on the x axis as the corresponding protein measurement.
Selected phosphosites of interest are indicated. Note, the few phosphosites
for which the corresponding protein was not quantified were assigned a
protein fold change of ‘‘0’’ for graphical purposes. See also Table S7.
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proteins. Among the most highly phosphorylated proteins in
our study was Hmgcs2, the enzyme that catalyzes the rate-
limiting step in ketogenesis (Reed et al., 1975). We identified
ten phosphorylated residues on Hmgcs2 (Figure 2B), and phos-Cell Mphorylation abundance on five of these sites exhibited significant
changes in at least one comparison (q < 0.1). Two of these sites,
S433 and S456, are conserved in the human ortholog (HMGCS2)
and had phosphorylation patterns that suggest a potential
contribution to the elevated ketone body levels we observe in
obese diabetic BTBRmice (Figure 6A), leading us to hypothesize
that these phosphosites might regulate enzyme activity. Due to
a primary sequence difference between B6 and BTBR mice
near the S433 phosphorylation site (Figure S4A), we were unable
to directly measure the relative abundance of this site between
strains using the iTRAQ system. However, spectral counts sug-
gest that phosphorylation of this site is only prominent in B6
animals (Figure S4A), where it exhibits an obesity-induced in-
crease in 10-week-old mice (q < 0.03). Alternately, S456 exhibits
an obesity-induced increase in both strains, with a more pro-
nounced increase in BTBR mice (Figures 6B and 6C). As high-
lighted in Figure 6D, S456 on Hmgcs2 falls within consensus
motifs for both protein kinase A (PKA) and caseine kinase
2 (CK2)—two of the kinases predicted to be active in our
mitochondrial survey (Figure 5, Figure S3) and that have previ-
ously been associated with mitochondrial regulation (Acin-Perez
et al., 2009; Schmidt et al., 2011; Zhao et al., 2011).
To evaluate the effects of these dynamic phosphorylation
events on Hmgcs2 enzymatic activity, we performed bio-
chemical assays on a series of human HMGCS2 variants. We
mutated each phosphorylated residue to an acidic residue
(aspartic acid or glutamic acid) to mimic phosphorylation
(S433D, S456D/E) or to a nonphosphorylatable residue (alanine
or methionine) to mimic dephosphorylation (S433A, S456A/M).
We immunoprecipitated these mutants, along with wild-type
and catalytically inactive (C166A) HMGCS2, from HEK293 cells
and tested the activity of each variant in an in vitro enzymatic
assay (Andrew Skaff and Miziorko, 2010). As seen in Figure 6E,
the phosphomimetics for serine 456 each resulted in at least
a 60% increase in enzyme activity over wild-type and the
S456A variant that was consistent across multiple substrate
concentrations (Figure 6F) and protein amounts (Figure S4C).
A third variant (S456M), which approximates the steric change
of the phosphomimetics without conferring a negative charge,
also had no increase in enzyme activity (Figure 6E). Interest-
ingly, the S433 phosphomimetic had no change in activity (Fig-
ure 6E, Figure S4B), suggesting that phosphorylation on this site
has a role distinct from directly modifying Hmgcs2 enzymatic
activity.
Given the kinase motifs surrounding S456 (Figure 6D), we
tested the ability of PKA to activate enzyme activity by incubating
it with wild-type HMGCS2 and each of the S456 variants before
repeating the activity assays. As seen in Figure 7A, only wild-type
HMGCS2, which possesses a phosphorylatable serine 456, had
its activity increased by PKA. MS analysis of the PKA-treated
HMGCS2 verified that serine 456 was indeed phosphorylated
by this treatment (Figure 7B), and that the untreated enzyme
had no detectible phosphorylation on this site. CK2 increased
HMGCS2 activity to an even greater extent (Figure 7A) than
PKA, with this effect likewise abrogated by mutation of S456.
This result is consistent with the human ortholog of HMGCS2
(Figure 7B) having a slightly weaker PKA consensus site around
S456 than the mouse ortholog (Figure 6B), while maintaining
a strong CK2 consensus sequence.etabolism 16, 672–683, November 7, 2012 ª2012 Elsevier Inc. 677
Figure 5. Protein Phosphorylation Measurements Reveal Potential
Kinase-Substrate Relationships
(A) Selected kinases and their substrate consensus sequences from the
PHOSIDA database are indicated, with X indicating any amino acid and red
lowercase letters indicating the phosphorylated residues. The number of
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678 Cell Metabolism 16, 672–683, November 7, 2012 ª2012 ElsevierWe next sought to determine if S456 phosphorylation is
important for the activation of HMGCS2 in response to
increased ketogenic demand. To do so, we immunoprecipitated
WT and mutant HMGCS2 from HEK293 cells cultured in either
standard or ketogenic media, which increases ketone body
production (Figure S5A) (Sengupta et al., 2010). WT HMGCS2
was approximately 2-fold more active when purified from cells
grown in ketogenic media (p < 0.001) (Figure 7C). This effect
was ablated with mutation of S456 (Figure 7C), with neither
the S456A nor the S456D mutants showing a change in activity
between media conditions (note S456D activity was still greater
than S456A activity, consistent with Figures 6E and 6F). Disrup-
tion of either the basic (K453A) or acidic (E458A) kinase motifs
also abrogated HMGCS2 activity in ketogenic media (Figure 7D),
although variants missing proline 457 behaved similarly to wild-
type (Figure S7D). Moreover, WT HMGCS2 purified from 293
cells grown in ketogenic media could not be further activated
by in vitro phosphorylation with CK2, suggesting maximal
phosphorylation occupancy of S456 in ketogenic conditions
(Figure 7E).
As a final test of the importance of S456 phosphorylation
on the activation of HMGCS2, we measured ketone body
production from HEK293 cells expressing HMGCS2 variants.
In standard media, 293 cells produce miniscule amounts of
b-HB, in large part due to the nearly complete absence of
HMGCS2 (Figure S5C). However, expression of exogenous
HMGCS2 results in significant b-HB production, which is further
activated by ketogenic media (Figure S5A) (Sengupta et al.,
2010). Here, we expressed wild-type, S456A, or S456D
HMGCS2 in 293 cells (Figure S5B) under both standard and
ketogenic conditions and measured b-HB production after
72 hr. Consistent with our in vitro activity results (Figure 7C),
mutation of S456 significantly attenuated the fold-change in-
crease in ketone body production following a switch to ketogenic
media (Figure 7F). Also consistently, cells harboring the 456D
mutant had a greater ketogenic output than those with the
S456A mutant (Figure 7G). Interestingly, cells expressing wild-
type HMGCS2 had the greatest total b-HB production. This
suggests that, in vivo, mutation of this site might affect other
properties of HMGCS2, such as proper mitochondrial localiza-
tion, interactions with other proteins, or its modification by other
known PTMs (e.g., acetylation, succinylation, or palmitoylation)
(Kostiuk et al., 2008; Quant et al., 1990; Shimazu et al., 2010).
Nonetheless, the combination of our MS analyses, in vitroMS/MS-identified mitochondrial phosphorylation sites and phosphoproteins
(MitoCarta) that satisfy the sequence preferences for each kinase are listed.
(B) Motif-X logo indicating amino acid sequence motifs overrepresented
around identified phosphorylation sites on MitoCarta proteins. The red letters
at position ‘‘0’’ indicate the phosphorylated residue, and the probability of an
amino acids being present within 17 residues to each side is represented by
the height of the respective single-letter symbol. Residues that are ‘‘fixed’’ in
the motif (or are always present) span the entire height of the logo and are
shown in black (unfixed residues are in gray).
(C) Relative changes in kinase activity were predicted by averaging phos-
phosite quantitation for all substrates (mitochondrial and nonmitochondrial)
phosphorylated on PKA (left) or CK2 (right) consensus sites. Values are ex-
pressed as fold change (10 week/4 week) on a log2 scale in both the lean (light
gray bars) and obese (black bars) conditions, with asterisks (*) indicating
significance at p < 0.05. See also Figure S3.
Inc.
Figure 6. Identification of Serine 456 on Hmgcs2 as a Candidate Regulatory PTM
(A) b-hydroxybutyrate (b-HB) levels were measured in serum from lean and obese B6 and BTBR mice at 10 weeks of age. Error bars indicate SEM.
(B) Single-scan MS2 spectrum and manual validation identifying phosphorylation of serine 456 (S456) on mouse Hmgcs2. The inset shows iTRAQ reporter ions
providing relative quantitation of S456 phosphorylation in lean (L) and obese (O) mice from the univariate study.
(C) Relative phosphorylation levels onHmgcs2S456 in themultivariate experiment. Data points indicate condition-specificmean, relative to the averageof all eight
conditions (log2 scale), with error bars indicating the SD of all replicates quantified. Note, conditions highlighted in black are the same as those assessed in (A).
(D) Schematic of Hmgcs2 primary sequence highlighting identified phosphorylated residues, including the PKA and CK2 consensus site at S456.
(E) Activity of FLAG-tagged wild-type (WT) HMGCS2 and the indicated mutants (C166A is a catalytically dead control) and GFP, using 1,000 mM Ac-CoA as the
substrate. Activity is expressed as a percent of WT, and error bars indicate SD of triplicate analyses.
(F) Enzyme activity kinetic curve for FLAG-tagged wild-type (WT), S456A, S456D, and C166A HMGCS2. Error bars indicate SD. Kinetic parameters for selected
Hmgcs2 variants are shown at the right.
Asterisks (*) indicate significance at p < 0.05. See also Figure S4.
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strongly support a role for HMGCS2 S456 phosphorylation in
enhancing ketogenic output.
Conclusion
We have established a quantitative proteomic compendium that
charts dynamic changes in mitochondria across a series of con-Cell Mtrasting biological states. This resource, termedMitoMod (http://
mitomod.biochem.wisc.edu), captures both protein and phos-
phoprotein alterations, and is further leveraged by matched
microarray data from the same tissue samples (Keller et al.,
2008). These measurements enable the interrogation of post-
transcriptional and posttranslational mechanisms important for
mitochondrial adaptation. Additionally, our quantitative dataetabolism 16, 672–683, November 7, 2012 ª2012 Elsevier Inc. 679
Figure 7. Phosphorylation of Serine 456 on HMGCS2 Increases Enzyme Activity and Is Induced during Ketogenesis
(A) Percent increase in HMGCS2 activity after performing in vitro kinase reactions with either PKA (left) or CK2 (right). Error bars indicate SEM.
(B) Mass spectrum (average of 25 MS2 scans) identifying phosphorylation of S456 on human HMGCS2 after reaction with PKA seen in (A).
(C) HMGCS2 enzyme activity at 1,000 mM Ac-CoA after immuoprecipitation from HEK293 cells grown in either standard or ketogenic media for 72 hr. Values are
normalized to WT in standard media. Error bars indicate SEM.
(D) Activity of HMGCS2 kinase recognition motif mutants, using same assay as in (C).
(E) Enzyme activity kinetic curve for FLAG-tagged WT HMGCS2 immunoprecipitated from HEK293 cells cultured for 72 hr in either standard (S) or ketogenic (K)
media, and subsequently incubated with (+) or without () CK2 in an in vitro assay. Error bars indicate SD. Kinetic parameters are shown in the inset.
(F) Fold increase in b-hydroxybutyrate (b-HB) levels produced by HEK293 cells expressing HMGCS2 variants upon culturing in ketogenic (K) media for 72 hr,
relative to standard (S) media.
(G) b-hydroxybutyrate (b-HB) levels in S456A (gray) or S456D (red) mutant HMGCS2-transfected HEK293 cells over a time course of culturing in ketogenic media.
Asterisks (*) indicate significance at p < 0.05. See also Figure S5.
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mouse strains and varying biological states, including the transi-
tion from adolescence to adulthood, the onset of obesity or T2D,
and the response to acute fasting/refeeding. We demonstrate
the utility of this resource by identifying Hmgcs2 S456 as
an important phosphorylation target that enhances enzymatic
activity in response to increased ketogenic demand.
While our work provides an in-depth assessment of mitochon-
drial phosphorylation, much remains to be learned about the
nature and importance of this modification in regulating mito-
chondrial activities. Most notably, although our motif analyses
have aided in identifying potential kinases responsible for the680 Cell Metabolism 16, 672–683, November 7, 2012 ª2012 Elsevierobserved phosphorylation events, definitive demonstration of
kinases residing within—or translocating to—mitochondria has
largely remained elusive (O’Rourke et al., 2011; Pagliarini and
Dixon, 2006). As such, with few exceptions, we do not yet under-
stand when, where, and how mitochondrial proteins are phos-
phorylated. Second, as PTMs are typically involved in rapid
modulation of protein function, it will be important to continue
to profile how the mitochondrial phosphorylation events we
have identified change in response to other acute stresses,
such as hypoxia, inflammation, and elevated ROS levels. Finally,
because certain phosphorylation sites remain difficult to detect
(including those within highly acidic peptides or those containingInc.
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Quantitative Mitochondrial Phosphoproteomicslabile histidine phosphorylation) (Grimsrud et al., 2010b), it will be
important to continue profiling the mitochondrial phosphopro-
teome with new MS technologies, such as negative electron-
transfer dissociation (McAlister et al., 2012). Moving forward,
we aim to address these issues, as well as to explore the inter-
relationship of phosphorylation with other prominent PTMs,
including acetylation, methylation, and glycosylation. In doing
so, we aim to elucidate the signaling networks that manipulate
mitochondrial function, and to identify specific signaling mole-
cules that can be targeted therapeutically to help remedy mito-
chondrial dysfunction in metabolic disease.
EXPERIMENTAL PROCEDURES
Animal Models
Breeding, sacrificing, and tissue harvesting ofmice were described previously,
for both the univariate (Zhao et al., 2009) and multivariate (Keller et al., 2008)
experiments. Briefly, male mice were bred and housed in an environmentally
controlled facility. Animals were provided access to water and standard rodent
chow (Purina number 5008), except during a fasting period (8 a.m. to noon) in
order to obtain plasma at 4 or 10weeks of age, after which theywere sacrificed
by decapitation. Liver tissue was dissected, flash frozen with liquid N2, and
stored at 80C until use. For the fasting/refeeding study, lean (wild-type)
B6 mice (9 weeks of age) were fasted overnight (16 hr), after which half of
the animals were allowed to feed ad libitum for 2 hr prior to sacrifice (note, fresh
liver tissue was used for this experiment). The mice were kept in accordance
with the University of Wisconsin–Madison Research Animals Resource Center
and the NIH guidelines for care and use of laboratory animals.
Proteomics Sample Preparation
Tissue sections from each liver were used for mitochondrial enrichment, using
previous methods (Pagliarini et al., 2008) modified by the addition of phospha-
tase inhibitors. Pelleted proteins (0.5 mg/sample) were digested as described
(Grimsrud et al., 2010a), with modifications including sequential use of LysC
and trypsin to ensure robust digestion. Peptides were labeled with a unique
eight-plex iTRAQ reagent, and samples were mixed in batches of eight.
Peptides were separated by strong cation exchange chromatography (SCX),
and after aliquots were removed for unmodified peptide quantitation, immobi-
lized metal affinity chromatography (IMAC) was performed on each fraction to
enrich for phosphopeptides as described (Phanstiel et al., 2011).
Large-Scale Tandem MS Data Collection and Analysis
Nano-LC-MS/MS analysis was performed on an ETD-enabled LTQ Orbitrap
Velos (Thermo Fisher Scientific). We performed data-dependent analysis
with methods developed previously for improved quantitation accuracy with
isobaric tags, relying on either postacquisition filtering (PAF) (Phanstiel et al.,
2011) or real-time filtering (RTF) (Wenger et al., 2011a) of precursors, for the
univariate and multivariate experiments, respectively. Here, at least two runs
using all HCD (Olsen et al., 2007) fragmentation were performed for each
sample. An additional run using back-to-back ETD (Syka et al., 2004) and
HCD on each precursor was performed on each phosphopeptide fraction.
For the fasting/refeeding experiment, peptide and phosphopeptide fractions
were subjected to two runs: one used all HCD (applying PAF), and one used
HCD along with our recently developed QuantMode method, which applies
gas phase purification of precursors during data collection (Wenger et al.,
2011a). We used our custom software COMPASS (Wenger et al., 2011b) to
search the tandem MS data against a concatenated target-decoy UniProt
mouse database, filter peptide identifications to 1% FDR, normalize iTRAQ
reporter ion intensities, group peptides to parsimonious protein groups at
1% FDR, localize phosphorylation sites to specific residues at 95% proba-
bility, and sum reporter ion intensities for all spectra identifying the same
protein or phosphoisoform in a given replicate.
Statistical Analysis
Microsoft Access and Excel were utilized for statistical analysis of protein and
phosphorylation measurements. We evaluated the significance of a givenCell Mprotein, phosphoisoform, or normalized phosphoisoform change by com-
puting p values, assuming a log-normal distribution for measurement error.
Each comparison was made without adjustment for other factors or compar-
isons. We corrected for multiple hypothesis testing by computing a false
discovery rate (FDR, q value) in which we assumed two populations (changing
and unchanging) and that the unchanging population had p values which are
uniformly distributed from 0 to 1 (Figure S1E). FDRs (q values) were calculated
separately for each measurement type. All protein and phosphoprotein
measurements, as well as motif and kinase activity predictions, are listed in
Table S1, Table S2, Table S3, Table S4, Table S5 (see Figure S1A for descrip-
tions of all comparisons), and Table S7. Crosses (y) indicate significance at
q < 0.1 (applicable to all proteomic/phosphoproteomic measurements), with
asterisks (*) indicating significance at p < 0.05 (applicable to predictions in
kinase/motif changes and biochemical assays).MitoMod Database Development
All of the proteomic/phosphoproteomic data generated from this study were
utilized to develop an interactive website, called MitoMod, that is freely avail-
able at http://mitomod.biochem.wisc.edu. The entire analyzed data set, as
well as the raw MS data (Thermo .raw files) and a table of all our iTRAQ tag-
mouse pairings, can also be downloaded for independent analysis.Biochemical Assessment of HMGCS2 Regulation
HEK293 cells were cultured in DMEM supplemented with 10% FBS and anti-
biotics. All expression constructs were derived from pcDNA3.1 (Invitrogen) as
described previously (Shimazu et al., 2010). Site-directed mutagenesis to
create HMGCS2 variants was performed using standard PCR-based cloning
techniques (constructs were verified by DNA sequencing). Transfections
were performed at 70% confluence, and cells were lysed and protein sub-
jected to immunoblotting with HRP-conjugated anti-FLAG antibody to assess
expression. For ketogenic media (KM) experiments (Sengupta et al., 2010),
cells were grown in KM (DMEMwithout the addition of FBS, and supplemented
with 2mM sodium octanoate and 5 mMWY-14643) from 24 to 72 hr after trans-
fection, media collected at each time point, and ketone bodiesmeasured using
an Autokit Total Ketone Bodies assay (Wako). FLAG-tagged HMGCS2 was
purified and its activity assessed as described previously (Shimazu et al.,
2010; Andrew Skaff and Miziorko, 2010). See the Supplemental Experimental
Procedures for further details.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, seven tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://dx.doi.org/10.1016/j.cmet.2012.10.004.ACKNOWLEDGMENTS
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